COVID-19 is a serious infectious disease, which poses a great threat to human health and social stability. In order to comprehensively fight the COVID-19 epidemic, local medical insurance departments have also issued a series of reimbursement policies accordingly, so as to promote the majority of patients to better receive medical services such as testing and treatment. Specifically, the testing expenses in COVID-19 can be included in the scope of medical insurance reimbursement, and the related treatment expenses and drug expenses can also be supported by corresponding reimbursement. In addition, in order to better protect the rights and interests of patients, many places have also introduced additional medical assistance policies to provide more support and help to poor patients. At the same time, the reimbursement policy for outpatient special diseases has also been adjusted to provide greater support and help for epidemic prevention and control. In some areas, the implementation period of outpatient special disease reimbursement policy has even been extended to facilitate more patients to enjoy the corresponding medical insurance reimbursement policy.
How does the COVID-19 epidemic affect the medical insurance fund? The epidemic situation in COVID-19 has had a certain impact on the medical insurance fund. On the one hand, the outbreak of the epidemic has increased the pressure and burden on medical institutions; On the other hand, the hospital's expenditure on prevention and control materials, equipment and personnel training has also increased significantly, requiring more funds. However, with the support of the state and the active adjustment of local medical insurance departments, the overall operation of medical insurance funds is relatively stable, and there are no major risks and crises.
In response to the epidemic situation in COVID-19, local medical insurance departments issued corresponding reimbursement policies, including the expenses of testing, treatment and medicines in COVID-19, and extended the implementation period of reimbursement policies for special diseases in outpatient clinics. Although the epidemic had a certain impact on the medical insurance fund, there was no big risk and crisis.
Legal basis:
Article 12 of the Law of People's Republic of China (PRC) on the Prevention and Control of Infectious Diseases All units and individuals in People's Republic of China (PRC) must accept the investigation, inspection, sample collection and isolation treatment of infectious diseases by disease prevention and control institutions and medical institutions, and provide relevant information truthfully. Disease prevention and control institutions and medical institutions shall not disclose relevant information and materials involving personal privacy. Where the administrative department of health and other relevant departments, disease prevention and control institutions and medical institutions illegally implement administrative management or prevention and control measures and infringe upon the legitimate rights and interests of units and individuals, the relevant units and individuals may apply for administrative reconsideration or bring a lawsuit according to law.